Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
Status:
Terminated
Trial end date:
2021-05-11
Target enrollment:
Participant gender:
Summary
PRECISION-HD1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled
study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
of single and multiple doses of WVE-120101 in adult patients with early manifest Huntington's
disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362307 (SNP1).